Product Description: TRX-518 is a humanized agonist antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR). TRX-518 specifically targets GITR⁺ Tregs and CD45RA⁻Foxp3⁺ effector Tregs (eTregs) among regulatory T cells (Tregs), reducing the number of Tregs in circulation and within tumors. TRX-518 is promising for research of cancers[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Zappasodi R, et al. Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial[J]. Cancer Research, 2017, 77(13_Supplement): CT018-CT018.
Molecular Weight: N/A
Research Area: Cancer
Target: TNF Receptor